

Lampiran Peer Review Korespondensi Proses Submit Publikasi Internasional

Nama Jurnal : Drug Research

Volume : 2013; 63(10): 515-520

No. ISSN : 2194-9379

DOI : <https://dx.doi.org/10.1055/s-0033-1347188>

H Index : 65

Impact Factor : 0.588

SJR Index : 0,326

Reputasi : SCOPUS (Q3)

Judul Artikel : Simultaneous Treatment with Azelnidipine and Olmesartan Inhibits Apoptosis of H1-1 Cardiac Myocytes Expressing E334k cMyBPC

Item	Halaman
Submission Received + Original Paper (Jan 8, 2013)	2
Comment Reviewer (Jan 31, 2013)	14
Respond to Reviewer (Feb 12, 2013)	18
Accepted for Publication (May 3, 2013)	21
Paper has been Published online (May 4, 2013)	22



bahrudin udin <bahrudin00@gmail.com>

Arzneimittelforschung/Drug Research - Manuscript ID AMF-2013-01-021332 messages

drugresearch@editorialoffice.co.uk <drugresearch@editorialoffice.co.uk>

Tue, Jan 8, 2013 at 9:33 PM

To: bahrudin00@gmail.com, nikedata@med.tottori-u.ac.jp, sulis_bayu@yahoo.com, maharani.nani@gmail.com, peili-li@med.tottori-u.ac.jp, mochamadalis@gmail.com, ahase5@yahoo.co.jp, m12045sakata@yahoo.co.jp, ryocky0518@gmail.com, yshirayo@med.tottori-u.ac.jp, ykazuhiro@med.tottori-u.ac.jp, ninomiya@med.tottori-u.ac.jp, hisatome@med.tottori-u.ac.jp

08-Jan-2013

Dear Author/Co-Author

A manuscript entitled "Simultaneous administration of azelnidipine and olmesartan ameliorates apoptosis of HL-1 cardiac myocytes expressing E334K cMyBPC" has been successfully submitted online by Dr. udin bahrudin and is presently being given full consideration for publication in Arzneimittelforschung/Drug Research.

The manuscript ID is: AMF-2013-01-0213

You can view this manuscript and check the status of papers you have authored/co-authored at any time by checking your "Author Center" after logging in to <http://mc.manuscriptcentral.com/amf> .

If there are any changes in your street address or e-mail address, please log in to Manuscript Central and edit your user information as appropriate.

Please mention the above manuscript ID in all future correspondence or when calling the Editorial Office for questions.

Thank you for submitting your manuscript to Arzneimittelforschung/Drug Research.

Yours sincerely,
Gill Smith
Editorial Office
Arzneimittelforschung/Drug Research
drugresearch@editorialoffice.co.uk

bahrudin udin <bahrudin00@gmail.com>

Sun, Feb 17, 2013 at 2:01 PM

To: bahrudin <bahrudin@med.tottori-u.ac.jp>

Cc: nikedata@med.tottori-u.ac.jp, sulis_bayu@yahoo.com, maharani.nani@gmail.com, peili-li@med.tottori-u.ac.jp, mochamadalis@gmail.com, ahase5@yahoo.co.jp, m12045sakata@yahoo.co.jp, ryocky0518@gmail.com, yshirayo@med.tottori-u.ac.jp, ykazuhiro@med.tottori-u.ac.jp, ninomiya@med.tottori-u.ac.jp, hisatome@med.tottori-u.ac.jp

Dear all authors,

I would like to inform you that our manuscript has been reviewed and the result is positive. The editors and reviewers requested a minor revision.

For completing the submission of the revised manuscript, the journal requests all authors to sign a statement of conflict of interest. Please could you fill in and sign the attached form? Then, please send back to me via email as soon as possible.

I am looking forward to hearing news from you.

Sincerely,

Udin Bahrudin

[Quoted text hidden]


--

Bahrudin, MD, PhD

Center of Biomedical Research (CEBIOR) and Dept. of Anatomy
Faculty of Medicine, Diponegoro Univ.
Jl. Dr. Sutomo 18 Semarang, Indonesia
Tel. +62-24-76487686, Mobile +62-81228000876
Email: bahrudin00@gmail.com
Post mail: Jl. Kanfer Raya no. 4A Banyumanik, Semarang

2 attachments

 **Thieme_conflict_of_interest.pdf**
129K

 **Thieme_conflict_of_interest.doc**
81K

Mail Delivery Subsystem <mailer-daemon@googlemail.com>
To: bahrudin00@gmail.com

Sun, Feb 17, 2013 at 2:01 PM

Delivery to the following recipient failed permanently:

bahrudin@med.tottori-u.ac.jp

Technical details of permanent failure:

Google tried to deliver your message, but it was rejected by the server for the recipient domain med.tottori-u.ac.jp by daisen3.tottori-u.ac.jp. [160.15.14.7].

The error that the other server returned was:

550 5.1.1 <bahrudin@med.tottori-u.ac.jp>: Recipient address rejected: undeliverable address: host grape.med.tottori-u.ac.jp[160.15.183.9] said: 550 5.1.1 <bahrudin@med.tottori-u.ac.jp>: Recipient address rejected: User unknown in local recipient table (in reply to RCPT TO command)

----- Original message -----

DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed;
d=gmail.com; s=20120113;
h=mime-version:x-received:in-reply-to:references:date:message-id
:subject:from:to:cc:content-type;
bh=inuavVgQHeUzW1kM0E41Y08L80af7ijeqISIAAdj8Tjo=;
b=IQ2PMiMM2s6MpNc4z3zDA9+FHPOq/9lo60qCBqmXT9Pt2JkjQRr5gS+3EL/pVvwyVob
TaemuoRIJWc37URJVnvja8WeK44lpAH8RENI+bzPzUEodkeuKls63wszV56sXfNRcUu/
TcKydyOG70es/6Vu/kTMKk6jLiLZo+P8np+03PV9CghYp56yRNR2shQksGiOaHwjYJ8
O2CE6i1Bh8TA/tiN4UCB/KML4/3s25ogFFGCaV4JnbSwUSwYDMNz0b3zDk/2/IQ45c5H
PyWc4kzqP07NOF1ywTVucHjjagud18wZMpkSM7sKXF7Era9w3jnX1JWx/DmZm828C0gw
7wyw==

MIME-Version: 1.0

X-Received: by 10.224.39.139 with SMTP id g11mr3775076qae.35.1361084511325;

Sat, 16 Feb 2013 23:01:51 -0800 (PST)

Received: by 10.49.24.19 with HTTP; Sat, 16 Feb 2013 23:01:50 -0800 (PST)

In-Reply-To: <603797830.377911357655591747.JavaMail.wladmin@tss1be0092>

References: <603797830.377911357655591747.JavaMail.wladmin@tss1be0092>

Date: Sun, 17 Feb 2013 16:01:50 +0900

Message-ID: <CAPDfYac+RxTNIsw7EpiKJ_Eg-KMvMYzVPzqOPqEkiL6rsgcvdg@mail.gmail.com>

Subject: Re: Arzneimittelforschung/Drug Research - Manuscript ID AMF-2013-01-0213

From: bahrudin udin <bahrudin00@gmail.com>

To: bahrudin <bahrudin@med.tottori-u.ac.jp>

Cc: nikeda@med.tottori-u.ac.jp, sulis_bayu@yahoo.com, maharani.nani@gmail.com,
peili-li@med.tottori-u.ac.jp, mochamadalis@gmail.com, ahase5@yahoo.co.jp,
m12045sakata@yahoo.co.jp, ryocky0518@gmail.com, yshirayo@med.tottori-u.ac.jp,
ykazuhiko@med.tottori-u.ac.jp, ninomiya@med.tottori-u.ac.jp,
hisatome@med.tottori-u.ac.jp

Content-Type: multipart/mixed; boundary=20cf3074b14ece8fff04d5e62ec3

[Quoted text hidden]

Hisatome <hisatome@med.tottori-u.ac.jp>
To: bahrudin udin <bahrudin00@gmail.com>

Sun, Feb 17, 2013 at 5:07 PM

Dear Udin sensei

I attached my COI with my signature.

When it has been accepted, please let me the price of reprints in advance, since Pharmaceutical company will pay them.

from Ichiro

From: bahrudin udin

Sent: Sunday, February 17, 2013 4:01 PM

To: bahrudin

Cc: nikeda@med.tottori-u.ac.jp ; sulis_bayu@yahoo.com ; maharani.nani@gmail.com ; peili-li@med.tottori-u.ac.jp ; mochamadalis@gmail.com ; ahase5@yahoo.co.jp ; m12045sakata@yahoo.co.jp ; ryocky0518@gmail.com ; yshirayo@med.tottori-u.ac.jp ; ykazuhiro@med.tottori-u.ac.jp ; ninomiya@med.tottori-u.ac.jp ; hisatome@med.tottori-u.ac.jp

Subject: Re: Arzneimittelforschung/Drug Research - Manuscript ID AMF-2013-01-0213

[Quoted text hidden]



bahrudin udin <bahrudin00@gmail.com>
To: Hisatome <hisatome@med.tottori-u.ac.jp>

Sun, Feb 17, 2013 at 5:54 PM

Hisatome Sensei,

1. Thank you for sending Col. But, could you please fill in your conflict of interest (**no. 1**) if you have, OR make a mark (circle) on **no. 2 (I have no conflict of interest to declare in connection with the contents of this manuscript)** if you have not?

2. After I finish the revision, could you help for checking the manuscript by English native speaker? It is recommended by reviewer.

Udin

[Quoted text hidden]

Kazuhiro Yamamoto <ykazuhiro@med.tottori-u.ac.jp>
To: bahrudin udin <bahrudin00@gmail.com>

Mon, Feb 18, 2013 at 5:44 AM

Dear Dr. Bahrudin

Thank you for your good news.

Attached is a form with my signature.

Sincerely

Kazuhiro Yamamoto, MD, PhD, FACC

Professor and Chairman

Division of Cardiovascular Medicine, Endocrinology and Metabolism
Department of Molecular Medicine and Therapeutics
Faculty of Medicine

Tottori University
86, Nishi-cho
Yonago 683-8503
Japan
TEL: +81-859-38-6517
FAX: +81-859-38-6519

Mail: ykazuhiro@med.tottori-u.ac.jp

From: bahrudin udin [mailto:bahrudin00@gmail.com]
Sent: Sunday, February 17, 2013 4:02 PM
To: bahrudin
Cc: nikeda@med.tottori-u.ac.jp; sulis_bayu@yahoo.com; maharani.nani@gmail.com; peili-li@med.tottori-u.ac.jp; mochamadalis@gmail.com; ahase5@yahoo.co.jp; m12045sakata@yahoo.co.jp; ryocky0518@gmail.com; yshirayo@med.tottori-u.ac.jp; ykazuhiro@med.tottori-u.ac.jp; ninomiya@med.tottori-u.ac.jp; hisatome@med.tottori-u.ac.jp
Subject: Re: Arzneimittelforschung/Drug Research - Manuscript ID AMF-2013-01-0213

Dear all authors,

[Quoted text hidden]

 **Yamamoto-sign.pdf**
128K

Haruaki Ninomiya <ninomiya@grape.med.tottori-u.ac.jp>
To: bahrudin udin <bahrudin00@gmail.com>

Mon, Feb 18, 2013 at 6:40 AM

Dear Udin,

Attached please find the document with my signature.

Regards,

Haruaki Ninomiya

From: bahrudin udin
Sent: Sunday, February 17, 2013 4:01 PM
To: bahrudin
Cc: nikeda@med.tottori-u.ac.jp; sulis_bayu@yahoo.com; maharani.nani@gmail.com; peili-li@med.tottori-u.ac.jp; mochamadalis@gmail.com; ahase5@yahoo.co.jp; m12045sakata@yahoo.co.jp; ryocky0518@gmail.com; yshirayo@med.tottori-u.ac.jp; ykazuhiro@med.tottori-u.ac.jp; ninomiya@med.tottori-u.ac.jp; hisatome@med.tottori-u.ac.jp
Subject: Re: Arzneimittelforschung/Drug Research - Manuscript ID AMF-2013-01-0213

[Quoted text hidden]

 **Ninomiya.pdf**
564K

Hisatome <hisatome@med.tottori-u.ac.jp>
To: bahrudin udin <bahrudin00@gmail.com>

Mon, Feb 18, 2013 at 6:43 AM

Udin sensei

I am sorry about it. I am sending the COI attacehd in this file.

[Quoted text hidden]

peilili <peili-li@med.tottori-u.ac.jp>
To: bahrudin udin <bahrudin00@gmail.com>

Mon, Feb 18, 2013 at 7:10 AM

Dear udin sann:

Congratulations!

I send my authorship agreement to you by an attached file.

See you in JCS

Peili Li

From: bahrudin udin

Sent: Sunday, February 17, 2013 4:01 PM

To: bahrudin

Cc: nikeda@med.tottori-u.ac.jp ; sulis_bayu@yahoo.com ; maharani.nani@gmail.com ; peili-li@med.tottori-u.ac.jp ; mochamadalis@gmail.com ; ahase5@yahoo.co.jp ; m12045sakata@yahoo.co.jp ; ryocky0518@gmail.com ; yshirayo@med.tottori-u.ac.jp ; ykazuhiro@med.tottori-u.ac.jp ; ninomiya@med.tottori-u.ac.jp ; hisatome@med.tottori-u.ac.jp

Subject: Re: Arzneimittelforschung/Drug Research - Manuscript ID AMF-2013-01-0213

[Quoted text hidden]



authorship agreement.jpg
917K

bahrudin udin <bahrudin00@gmail.com>
To: Hisatome <hisatome@med.tottori-u.ac.jp>

Mon, Feb 18, 2013 at 9:04 AM

Hisatome Sensei,

I am sorry, I could not find attachment in your email.

Udin

[Quoted text hidden]

bahrudin udin <bahrudin00@gmail.com>
To: peilili <peili-li@med.tottori-u.ac.jp>

Mon, Feb 18, 2013 at 9:10 AM

Dear Li San,

Thank you for sending the Col.

See you,

Udin

[Quoted text hidden]

bahrudin udin <bahrudin00@gmail.com>
To: Kazuhiro Yamamoto <ykazuhiro@med.tottori-u.ac.jp>

Mon, Feb 18, 2013 at 9:11 AM

Dear Prof Yamamoto,

Thank you for sending the Col.

Sincerely,

Udin

[Quoted text hidden]

bahrudin udin <bahrudin00@gmail.com>
To: Haruaki Ninomiya <ninomiya@grape.med.tottori-u.ac.jp>

Mon, Feb 18, 2013 at 9:12 AM

Dear Ninomiya Sensei,

Thank you for sending the Col.

Sincerely,

Udin

[Quoted text hidden]

Hisatome <hisatome@med.tottori-u.ac.jp>
To: bahrudin udin <bahrudin00@gmail.com>

Mon, Feb 18, 2013 at 9:30 AM

Udin sensei

I am sorry to miss the file. Here it is. Good luck.

[Quoted text hidden]



IMG.pdf
378K

sulistiyati bayu utami <sulis_bayu@yahoo.com>
To: bahrudin udin <bahrudin00@gmail.com>

Tue, Feb 19, 2013 at 7:43 AM

Assalamualaikum WR WB, mas Udin,

Alhamdulillah. Saya turut bunga atas kabar baiknya.
Berikut saya attach signature saya.

JCS ini mas Udin ke Yokohama bukan ? Apakah akan mampir ke Yonago ?

Wassalam,
Sulistiyati Bayu Utami

=====

--- On **Sat, 2/16/13**, **bahrudin udin** <bahrudin00@gmail.com> wrote:

From: bahrudin udin <bahrudin00@gmail.com>
Subject: Re: Arzneimittelforschung/Drug Research - Manuscript ID AMF-2013-01-0213
To: "bahrudin" <bahrudin@med.tottori-u.ac.jp>
Cc: nikeda@med.tottori-u.ac.jp, sulis_bayu@yahoo.com, maharani.nani@gmail.com, peili-li@med.tottori-u.ac.jp, mochamadalis@gmail.com, ahase5@yahoo.co.jp, m12045sakata@yahoo.co.jp, ryocky0518@gmail.com, yshirayo@med.tottori-u.ac.jp, ykazuhiro@med.tottori-u.ac.jp, ninomiya@med.tottori-u.ac.jp, hisatome@med.tottori-u.ac.jp

[Quoted text hidden]



Authors Signature Journal .JPG
1779K

bahrudin00@gmail.com <bahrudin00@gmail.com>
Reply-To: bahrudin00@gmail.com
To: sulistiyati bayu utami <sulis_bayu@yahoo.com>

Tue, Feb 19, 2013 at 8:35 AM

Terimakasih dik Sulis.
Iya, rencana ke Yokohama dan mungkin juga yonago. Ini lagi urus administrasi.

Udin
Powered by Telkomsel BlackBerry®

From: sulistiyati bayu utami <sulis_bayu@yahoo.com>
Date: Mon, 18 Feb 2013 16:43:03 -0800 (PST)
To: bahrudin udin <bahrudin00@gmail.com>
[Quoted text hidden]

Nani Maharani <maharani.nani@gmail.com>
To: bahrudin udin <bahrudin00@gmail.com>

Tue, Feb 19, 2013 at 9:20 AM

Dear Dr Bahrudin,

I am sorry for the late reply. Herewith I send you the statement which I have filled and signed.
Thank you very much.

Best regards,
Nani
[Quoted text hidden]



Nani_statement.jpeg
1882K

sulistiyati bayu utami <sulis_bayu@yahoo.com>
To: bahrudin00@gmail.com

Tue, Feb 19, 2013 at 9:22 AM

Ass, mas Udin.

Iya, mas.
Semoga perjalanannya lancar.
Bila memang akan ke Yonago, maka buku tabungan mas Udin akan saya serahkan ketika mas Udin ketika tiba di Yonago.

Selain itu mas. Apakah mas Udin berkenan bila saya menitip barang.
Yaitu cendramata untuk Sensei2 di sini. (berupa Wayang-wayang, mas)
Yg baru saja dibeli oleh Ibu saya.
Tapi sayangnya, tidak tahu siapa yg akan membawakannya ke Yonago.

Sebagai cendramata perpisahan.

Bila memang, mas Udin tidak ke Yonago, maka saya yg akan ke Yokohama untuk mengambil titipan saya.

Demikian mas, maturnuwun sebelumnya.

Sulis

=====
[Quoted text hidden]

bahrudin00@gmail.com <bahrudin00@gmail.com>
Reply-To: bahrudin00@gmail.com
To: sulistiyati bayu utami <sulis_bayu@yahoo.com>

Tue, Feb 19, 2013 at 10:04 AM

Dik Sulis, alternatif lain bisa diposkan via EMS atau DHL. Sy dulu seing dikirimi ortu dari Semarang. Gak mahal kok.

Bahrudin
Powered by Telkomsel BlackBerry®

From: sulistiyati bayu utami <sulis_bayu@yahoo.com>
Date: Mon, 18 Feb 2013 18:22:36 -0800 (PST)
To: <bahrudin00@gmail.com>
Subject: Re: Arzneimittelforschung/Drug Research - Manuscript ID AMF-2013-01-0213

[Quoted text hidden]

sulistiyati bayu utami <sulis_bayu@yahoo.com>
To: bahrudin00@gmail.com

Tue, Feb 19, 2013 at 10:15 AM

Ass, mas Udin.

Oh, begitu ya mas,,,
Terimakasih mas infonya,,, Akan saya beritahu beliau nya,,, :)

Wassalam,
Sulis

--- On **Mon, 2/18/13**, **bahrudin00@gmail.com** <bahrudin00@gmail.com> wrote:

[Quoted text hidden]

bahrudin00@gmail.com <bahrudin00@gmail.com>
Reply-To: bahrudin00@gmail.com
To: Nani Maharani <maharani.nani@gmail.com>

Tue, Feb 19, 2013 at 10:16 AM

Dik Nani,

Terimakasih. Tetapi tolong ditulis "your full name" dibawah judul artikel (terlewatkan).

Sy tunggu ya.

Bahrudin
Powered by Telkomsel BlackBerry®

From: Nani Maharani <maharani.nani@gmail.com>
Date: Tue, 19 Feb 2013 09:20:46 +0700
To: bahrudin udin<bahrudin00@gmail.com>
Subject: Re: Arzneimittelforschung/Drug Research - Manuscript ID AMF-2013-01-0213

[Quoted text hidden]

池田 信人 <nikedata@med.tottori-u.ac.jp>
To: bahrudin udin <bahrudin00@gmail.com>

Tue, Feb 19, 2013 at 12:35 PM

To Dr. Udin

Thank you for your E-mail.
I am sorry, I am late.
If you have a problem in this form, please let me know.

池田 信人
鳥取大学大学院医学系研究科
機能再生医科学専攻遺伝子再生医療学講座
再生医療学部門
E-mail:nikeda@med.tottori-u.ac.jp
Tel:0859-38-6445

 **Thieme_conflict_of_interest.doc**
84K

Yasuaki Shirayoshi <yshirayo@grape.med.tottori-u.ac.jp>
To: bahrudin udin <bahrudin00@gmail.com>

Tue, Feb 19, 2013 at 3:53 PM

Dear Udin,

I send the sign of statement back to you. I heard you will come back to Japan next month at the annual meeting of the Japanese circulation society. I will attend the meeting. So I am looking forward to seeing you there.

Sincerely,

Yasuaki Shirayoshi

From: bahrudin udin [<mailto:bahrudin00@gmail.com>]

Sent: Sunday, February 17, 2013 4:02 PM

To: bahrudin

Cc: nikeda@med.tottori-u.ac.jp; sulis_bayu@yahoo.com; maharani.nani@gmail.com; peili-li@med.tottori-u.ac.jp; mochamadalis@gmail.com; ahase5@yahoo.co.jp; m12045sakata@yahoo.co.jp; ryocky0518@gmail.com; yshirayo@med.tottori-u.ac.jp; ykazuhiro@med.tottori-u.ac.jp; ninomiya@med.tottori-u.ac.jp; hisatome@med.tottori-u.ac.jp

Subject: Re: Arzneimittelforschung/Drug Research - Manuscript ID AMF-2013-01-0213

Dear all authors,

[Quoted text hidden]

Yasuaki Shirayoshi <yshirayo@grape.med.tottori-u.ac.jp>
To: bahrudin udin <bahrudin00@gmail.com>

Tue, Feb 19, 2013 at 3:55 PM

Dear Udin,

I forget to attach the PDF file. Here you are.

From: bahrudin udin [mailto:bahrudin00@gmail.com]

Sent: Sunday, February 17, 2013 4:02 PM

To: bahrudin

Cc: nikeda@med.tottori-u.ac.jp; sulis_bayu@yahoo.com; maharani.nani@gmail.com; peili-li@med.tottori-u.ac.jp; mochamadalis@gmail.com; ahase5@yahoo.co.jp; m12045sakata@yahoo.co.jp; ryocky0518@gmail.com; yshirayo@med.tottori-u.ac.jp; ykazuhiro@med.tottori-u.ac.jp; ninomiya@med.tottori-u.ac.jp; hisatome@med.tottori-u.ac.jp

Subject: Re: Arzneimittelforschung/Drug Research - Manuscript ID AMF-2013-01-0213

Dear all authors,

[Quoted text hidden]

 **Udin .PDF**
364K

bahrudin udin <bahrudin00@gmail.com>

Tue, Feb 19, 2013 at 7:08 PM

To: Yasuaki Shirayoshi <yshirayo@grape.med.tottori-u.ac.jp>

Dear Shirayoshi Sensei,

Thank you for sending the Col.
See you in Yokohama.

Sincerely,
Udin

[Quoted text hidden]

bahrudin udin <bahrudin00@gmail.com>

Tue, Feb 19, 2013 at 7:13 PM

To: 池田 信人 <nikeda@med.tottori-u.ac.jp>

Dear Ikeda San,

Thank you for sending the Col, but please write the signature by hand writing, just like Col of Shirayoshi Sensei in the attachment. I send back your file with a little revision, and could you please send me again the scan or pdf file of your Col?

Thank you.

Udin


[Quoted text hidden]

[Quoted text hidden]

池田 信人
鳥取大学大学院医学系研究科
機能再生医科学専攻遺伝子再生医療学講座
再生医療学部門
E-mail: nikeda@med.tottori-u.ac.jp
Tel: 0859-38-6445

[Quoted text hidden]

2 attachments

 **Thieme_conflict_of_interest_Ikeda.doc**
82K

 **Col_Shirayoshi.PDF**
364K

ahase5@yahoo.co.jp <ahase5@yahoo.co.jp>

Tue, Feb 19, 2013 at 7:39 PM

Reply-To: ahase5@yahoo.co.jp

To: bahrudin udin <bahrudin00@gmail.com>

Dear Udin,

How are you? I haven't seen you for a long time.

I send your manuscript. Is this OK?
Sorry for the slow reply.

Please take good care of yourself.

Sincerely,

Akira Hasegawa

長谷川 輝
鳥取大学大学院 医学系研究科
機能再生医科学専攻 遺伝子再生医療学講座
再生医療学部門
博士後期課程1年

----- Original Message -----

From: bahrudin udin <bahrudin00@gmail.com>

To: bahrudin <bahrudin@med.tottori-u.ac.jp>

Cc: nikeda@med.tottori-u.ac.jp; sulis_bayu@yahoo.com; maharani.nani@gmail.com; peili-li@med.tottori-u.ac.jp; mochamadalis@gmail.com; ahase5@yahoo.co.jp; m12045sakata@yahoo.co.jp; ryocky0518@gmail.com; yshirayo@med.tottori-u.ac.jp; ykazuhiro@med.tottori-u.ac.jp; ninomiya@med.tottori-u.ac.jp; hisatome@med.tottori-u.ac.jp

Date: 2013/2/17, Sun 16:01

Subject: Re: Arzneimittelforschung/Drug Research - Manuscript ID AMF-2013-01-0213

[Quoted text hidden]

 **Udin .PDF**
323K

bahrudin udin <bahrudin00@gmail.com>
To: ahase5@yahoo.co.jp

Wed, Feb 20, 2013 at 5:17 AM

Dear Hasegawa San,

Thank you for sending the Col. It is fine.
See you next month. I am going to visit Yonago.

Udin

[Quoted text hidden]

Nani Maharani <maharani.nani@gmail.com>
To: bahrudin00@gmail.com

Thu, Feb 21, 2013 at 9:40 AM

Dear Dr Bahrudin,

Berikut saya kirimkan yang sudah saya cantumkan nama.

Terima kasih sebelumnya.

Salam,
Nani

On 2/19/13, bahrudin00@gmail.com <bahrudin00@gmail.com> wrote:

> Dik Nani,
>
> Terimakasih. Tetapi tolong ditulis "your full name" dibawah judul artikel
> (terlewatkan).
>
> Sy tunggu ya.
>
> Bahrudin
>
> Powered by Telkomsel BlackBerry®
>

[Quoted text hidden]



Statement_Nani.jpg
619K

bahrudin00@gmail.com <bahrudin00@gmail.com>
Reply-To: bahrudin00@gmail.com
To: Nani Maharani <maharani.nani@gmail.com>

Thu, Feb 21, 2013 at 9:42 AM

Terimakasih dik nani.
Kapan balik yonago?

[Quoted text hidden]

bahrudin00@gmail.com <bahrudin00@gmail.com>
Reply-To: bahrudin00@gmail.com
To: Nani Maharani <maharani.nani@gmail.com>

Thu, Feb 21, 2013 at 9:44 AM

Terimakasih dik nani.
Kapan balik yonago?

Bahrudin

Powered by Telkomsel BlackBerry®

-----Original Message-----

From: Nani Maharani <maharani.nani@gmail.com>
Date: Thu, 21 Feb 2013 09:40:10

[Quoted text hidden]

Nani Maharani <maharani.nani@gmail.com>
To: bahrudin00@gmail.com

Fri, Feb 22, 2013 at 3:47 PM

Dear dr Bahrudin,

Terimakasih juga, Dok. Saya tadinya berencana kembali ke Yonago akhir Maret. Tapi informasi dari Bgn Pendidikan Kedubes Jepang, saya baru bisa berangkat ke Jepangnya awal April plg cepat. Kalau mau berangkat sebelum April tiketnya beli sendiri. Jadi awal April baru akan berangkat. Tanggal pastinya belum bisa menentukan.

Salam,
Nani

[Quoted text hidden]



bahrudin udin <bahrudin00@gmail.com>

Drug Research - Decision on Manuscript ID AMF-2013-01-02133 messages

martin.wehling@medma.uni-heidelberg.de <martin.wehling@medma.uni-heidelberg.de>

Thu, Jan 31, 2013 at 1:34 PM

To: bahrudin00@gmail.com

31-Jan-2013

Dear Dr. bahrudin,

Manuscript ID AMF-2013-01-0213 entitled "Simultaneous administration of azelnidipine and olmesartan ameliorates apoptosis of HL-1 cardiac myocytes expressing E334K cMyBPC" you submitted to Drug Research has been reviewed. The comments of the reviewers are included at the bottom of this letter.

The reviewers have recommended publication, but also suggest some minor revisions to your manuscript. Therefore, I invite you to respond to the reviewers' comments and revise your manuscript.

To revise your manuscript, log into <http://mc.manuscriptcentral.com/drugres> and enter your Author Center, where you will find your manuscript listed under "Manuscripts with Decisions". Under "Actions," click on "Create a Revision". Your manuscript number has been appended to denote a revision.

You will be unable to make your revisions within the online submission system. Instead, revise your manuscript on your computer using a word processing program and save it on your computer. Please also highlight the changes to your manuscript within the document by using colored text.

If you have figure files please provide production quality images. For coloured & black/white figures 300dpi, for diagrams and line drawings 600dpi and we ask you provide them as gif, tif or jpeg files. Please upload your figure files individually.

Please could complete the Conflict of Interest form (downloadable from our website) ensuring that all authors have signed. You can either email this completed form to the editorial office (drugresearch@editorialoffice.co.uk) or upload it to the submissions system with your revised manuscript under the file designation 'supplementary files not for review'.

Once the revised manuscript is prepared, you can upload it and submit it through your Author Center.

When submitting your revised manuscript, you will be able to respond to the comments made by the reviewers in the space provided. Please use this space to document any changes you made compared to the original manuscript. In order to expedite the processing of the revised manuscript, please be as specific as possible in your response to the reviewers.

IMPORTANT: Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission.

Because we are trying to facilitate timely publication of manuscripts submitted to Drug Research, your revised manuscript should be uploaded within the next 12 weeks. If it is not possible for you to submit your revision within the next 12 weeks, please contact us. Otherwise, we may have to consider your paper as a new submission.

Once again, thank you for submitting your manuscript to Drug Research. We look forward to receiving your revision.

Sincerely,
Prof. Martin Wehling
Editor-in-Chief
Drug Research
martin.wehling@medma.uni-heidelberg.de

Reviewers' comments to author:

Reviewer: 1

Comments to the Author

- page 3 line 10: change 'to treat' to 'for treatment of'.

- page 4 line 1: Please name the ARBlocker "it is olmesartan".
- page 4 line 10: specify the direction of alteration of the cardiac ions channels.
- page 4 line 12 and page 7 line 1: change 'or' to 'and'.
- page 7 line 9: change 'antagonize' to 'antagonized'.
- page 7 line 18 and page 8 lines 5 & 12: cancel 'next'.
- page 7 lines 8 - 12 starting 'Pro-survival up to pathway' should be transferred to Discussion section.
- page 8 line 8: Transfer the sentence starting 'Taken together ' to Discussion section.
- page 8 lines 17/18: (approximately 32%) state significance.
- page 9 line 2: (approximately 36%) state significance.

Reviewer: 2

Comments to the Author

This study regarding the inhibitory effect of azelnidipine and olmesartan on apoptosis in cells expressing a mutant cMyBPC addressed a very interesting and important issue for cardiology, providing significant insights into the therapeutic strategy for hypertrophic cardiomyopathy. The methods and clinical significance are straightforward and clear. Nevertheless, I have a number of concerns and comments about the presentations and interpretations of the results.

General comments:

1. English grammar is generally good, but it could be improved. There are a lot of sentences and phrases to be checked and revised (particularly in the figure legends). I recommend that the manuscript is checked and revised by native English speakers who are familiar with this kind of study.

Specifically, for instance, in the title (as well as in abstract and text) the authors said that simultaneous administration of azelnidipine and olmesartan "ameliorates" apoptosis The word (verb) "ameliorate (apoptosis)" may be somewhat ambiguous, and other words (verbs) such as "inhibit (apoptosis)" or "prevent (apoptosis)" may be more straightforward and better.

Specific (minor) comments:

Abstract

1. Methods and Results, 1st sentence: Please provide the names of pro-apoptotic proteins "(p53, Bax and cytochrome c)" and those of anti-apoptotic proteins "(Bcl-2 and Bcl-XL)" in the first sentence.
2. Methods and Results, 2nd sentence: The author stated that "the beta blocker carvedilol normalized the level of p53 and Bcl-2, and the calcium channel blocker bepridil normalized that of Bcl-2". In Fig. 1f, however, the decrease in p53 with carvedilol (and increase in Bcl-2 with bepridil) does not come along with a sign indicating statistical significance (* or +). Please check whether this statement is correct and add the signs for statistical significance if necessary.
3. Methods and Results: The degrees of drug-induced reductions in the level of cytochrome c were given somewhat roughly (e.g., by "about" 30–40%). Please provide the mean values (or means \pm SEM) of the reductions, given that these values are shown as bar graphs (with error bars) in the figures.
4. The name of the CCB "azelnidipine" was given incorrectly (appeared as "azeldipine"). The same misprinting was also found in the text. Please check and correct this throughout the manuscript.

Introduction

5. p. 4, lines 8-11 ("Heterologous expression of E334K cMyBPC inhibited cellular proteasome activity, induced the accumulation of pro-apoptotic proteins, ...): Please state how E334K cMyBPC reduced the levels of anti-apoptotic proteins, while inhibiting proteasome activity. Do increased pro-apoptotic proteins yield the reduction in anti-apoptotic proteins?
6. Please state the aim of this study more clearly.

Methods

7. p. 5, line 9 (Western blotting): The term "cMyBPC" may be incorrect ("MYBPC3" may be correct) for transfection, given that "cMyBPC" is the name of the protein (not gene). Please check and correct if necessary.
8. p. 6, line 2 (Annexin V staining and flow cytometry): "E334K cMyBPC-transfected" may be replaced by "E334K MYBPC3-transfected" for the same reason as mentioned above.

Results

9. Please justify the concentrations (single dose) used for each agent. Are these comparable to the therapeutic plasma concentrations for individual agents? OR some other reasons derived from previous and/or preliminary studies (e.g., those yielding maximum attainable effects)?
10. p. 7, lines 14-15: The authors stated that the ratio of Bcl-2/pro-apoptotic proteins was “normalized” by any of the agents. However, this statement appears to be inconsistent with the results shown in Fig. 1g, where the ratio of Bcl-2/pro-apoptotic proteins was “normalized” only by the agent O, but not normalized (only partially restored) by the other agents. Please replace the word “normalized” by others such as “(completely or at least partially) restored”, and add the results of statistical analyses to show that the agents (particularly the agent C) are really effective.
11. p. 8, lines 1-3: The effective concentrations of azelnidipine in the dose-dependent effect experiment (Fig. 2a) were stated to be 0.1-0.3 M, while the concentration used for the single dose experiment (Fig. 1) was higher (1 M). However, the lower concentration of 0.1 M appeared to be highly effective in reduction of cytochrome c and attain nearly maximum effect (even more effective than 1 M as shown in Fig. 1f). Why the higher concentration of 1 M was used for the single dose experiment (Fig. 1)? Was the lower concentration of 0.1 M not high enough to attain the nearly maximum effects on other apoptosis-related proteins? In addition, the concentrations of olmesartan used in the dose-dependent effect experiment (Fig. 2b) were limited to 1 M, while a higher concentration of 10 M was used for the single dose experiment (Fig. 1). Was the effect of this agent saturated at 1 M? If this is the case, why the higher concentration of 10 M was used for the single dose experiment?
12. p. 8, lines 3-8: As in the abstract, the degrees of drug-induced reductions in the level of cytochrome c were given somewhat roughly (e.g., by “about” 30–40%). Please provide the means \pm SEM, given that these values are shown as bar graphs with error bars in Fig. 2. The authors also stated that either amlodipine (~0.3 μ M) or valsartan (~1 μ M) did not significantly reduce the level of cytochrome c (Fig. 2c–d), concluding that the effect of azelnidipine and olmesartan on normalization of cytochrome c level was not a class effect of CCB and ARB. In my opinion, however, one cannot conclude that amlodipine or valsartan is ineffective, or that the effect of azelnidipine and olmesartan was not a class effect of CCB and ARB, because amlodipine or valsartan actually reduced cytochrome c level by 10-20%, even though their effects were not statistically significant (which may become statistically significant when the number of examples are increased); i.e., they are less efficacious than azelnidipine or olmesartan but may still be effective. This may be supported by the fact that the co-application of amlodipine and valsartan significantly suppressed apoptosis as shown in Fig. 3. Please clarify the authors’ take on this point.
13. p. 8, lines 16-19: The degrees (%) of drug-induced reductions in the number of cells in the sub-G1 population or annexin V(+) cells were given somewhat roughly (e.g., by “approximately” 32%). Please provide the means \pm SEM, given that these values are shown as the bar graphs with error bars in Fig. 3.

Discussion

14. The discussion section is pretty long and may be somewhat redundant, as compared with other sections. In my opinion, therefore, this section should be shortened by deleting or shortening some of the statements. Specifically, the second paragraph describing the mechanisms of apoptosis in relation to mitochondrial dysfunction may be shortened, although it is very important and interesting.
15. p. 10, lines 2-4: The authors stated that both azelnidipine and olmesartan normalized the levels of proteins that regulate apoptosis such as p53, Bax, cytochrome c, “Bcl-2” and Bcl-XL in HL-1 cells expressing E334K cMyBPC (Fig. 1). According to Fig. 1d, however, they did not normalize the levels of “Bcl-2”. Please check and correct this (simply delete “Bcl-2”?).
16. p. 10, 12-13: As commented above, the statement “Although the level of cytochrome c was not reduced by either amlodipine or valsartan (Fig. 2), a combination of these drugs significantly reduced the numbers of apoptotic cells (Fig. 3)” may be problematic. What about the combined effect of amlodipine and valsartan on the level of cytochrome c (not on apoptosis)?
17. p. 11, line 13: Azelnidipine is again stated to normalize the levels of apoptosis-related proteins including “Bcl-2” in HL-1 cells expressing E334K cMyBPC. Please delete “Bcl-2”.
18. p. 12, lines 2-3: The statement “neither drug (carvedilol or bepridil) could normalize the normalization of the ratio of Bcl-2/ or Bcl-XL/pro-apoptotic proteins or the level of cytochrome c (Figure 1f–g)” is problematic (may be incorrect), and should be revised.
19. p. 12, line 11: Olmesartan is again stated to normalize the levels of apoptosis-related proteins including “Bcl-2” in HL-1 cells expressing E334K cMyBPC. Please delete “Bcl-2”.
20. p. 13, lines 8-11: As commented above, the statement “normalization of level of cytochrome c was not observed in cells treated with amlodipine or valsartan, indicating that the action of azelnidipine and olmesartan in HL-1 cells expressing E334K cMyBPC was independent from their class effect as CCB and ARB” may be problematic (incorrect) and should be revised.
21. p. 14, lines 1-5: The authors stated the report that the addition of azelnidipine to olmesartan was more effective

in reducing oxidant stress in hypertensive diabetic patients with chronic kidney disease than the addition of amlodipine [33] is in accordance with their finding that the combination of azelnidipine plus olmesartan was more efficient in suppressing apoptosis than the combination of amlodipine plus valsartan (Fig. 3). This statement may be problematic, given that the combination of amlodipine and olmesartan was not tested in this study.

Figures

22. Figure 1a-e: There are so many panels and bar graphs in Fig. 1a-f, with many bar graphs for E334K cMyBPC being duplicated in Fig. 1f. Too many panels may make it difficult for readers to properly understand the effects of the agents on the levels of apoptosis-related proteins in cells expressing the mutant cMyBPC. To more clearly show the roles of the agents in normalizing apoptosis-related proteins and preventing apoptosis in the cells with the mutant, in my opinion, the bar graph data for wild-type cMyBPC in Fig. 1a-e should be separated from those for the mutant. Given that the major aim of this study is to show the effects of the agents on cells with the mutant, the data for the wild-type cMyBPC (not discussed at all in the manuscript) may be omitted or removed to the supplementary materials (as for the bar graph, the data for the mutant in Fig. 1a-e or Fig. 1f may be enough). In addition, representative Western bolts may not be needed for all the apoptosis-related proteins.

23. Figure 1f: The signs indicating the statistical significance (* or +) are not properly assigned: They are out of alignment, and those for p53 of E.C and Bcl-2 of E.B are missing. Please check and correct them.

24. Figure 1g: I do not understand why the line graph (not bar graph) was used in this figure (the bar graph may be easier to understand and better). Please justify the use of the line graph, or use the bar graph instead.

25. Figure 2: The doses (concentrations) are not clearly given. Because all of the data are for the mutant (E), the labels "E.001"~"E.3" should be replaced by "0.001"~"0.3". For olmesartan (Fig. 2b) and valsartan (Fig. 2d), "E.1" on the extreme right should be "1.0" (not "0.1"). In addition, only one dose (concentration) may be enough for each agent in Fig. 2e.

26. Figure legends should be revised largely. Please check whether the concentrations of the agents (and the number of examples) are given correctly (particularly in Fig. 2).

Editor: Wehling, Martin
Comments to the Author:
(There are no comments.)

Comments Regarding Format from the Editorial Office:
Please amend the formatting of your manuscript as follows:

1) Please could you provide your figures as individual .doc, gif, tif or jpeg files. We require, for coloured & black/white figures, an image of 300dpi and for diagrams and line drawings 600dpi. The width of each image should be at least 650 pixels.

Please could you complete and return the Conflict of Interest form (downloadable from our website) ensuring that all authors have signed. You can either email this completed form to the editorial office (drugresearch@editorialoffice.co.uk) or upload it to the submissions system under the file designation 'supplementary files not for review'.

bahrudin udin <bahrudin00@gmail.com>
To: Hisatome <hisatome@med.tottori-u.ac.jp>

Tue, Feb 12, 2013 at 10:40 AM

Hisatome Sensei,

Here below I send the result of review of our manuscript submitted to the Drug Research.
I plan to finish the revision in the end of this week.

About the submission to the Bulletins of the Pharmaceutical Society, should we withdraw it?

Sincerely
Udin

[Quoted text hidden]

--

Bahrudin, MD, PhD
Center of Biomedical Research (CEBIOR) and Dept. of Anatomy
Faculty of Medicine, Diponegoro Univ.
Jl. Dr. Sutomo 18 Semarang, Indonesia
Tel. +62-24-76487686, Mobile +62-81228000876
Email: bahrudin00@gmail.com

Post mail: Jl. Kanfer Raya no. 4A Banyumanik, Semarang

久留 一郎 <hisatome@hotmail.co.jp>
To: udin <bahrudin00@gmail.com>

Wed, Feb 13, 2013 at 3:54 AM

Udin sensei

Thank you for your good news. Please revise your paper to response to the editor. Simulatanesously, would you please withdraw former jornal.

from Ichiro

Date: Tue, 12 Feb 2013 12:40:24 +0900
Subject: Fwd: Drug Research - Decision on Manuscript ID AMF-2013-01-0213
From: bahrudin00@gmail.com
To: hisatome@med.tottori-u.ac.jp

[Quoted text hidden]



bahrudin udin <bahrudin00@gmail.com>

Drug Research - Manuscript ID AMF-2013-01-0213.R1

1 message

drugresearch@editorialoffice.co.uk <drugresearch@editorialoffice.co.uk>

Tue, Apr 30, 2013 at 5:36 PM

To: bahrudin00@gmail.com, nikeda@med.tottori-u.ac.jp, sulis_bayu@yahoo.com, maharani.nani@gmail.com, kumi@med.tottori-u.ac.jp, peili-li@med.tottori-u.ac.jp, mochamadalis@gmail.com, ahase5@yahoo.co.jp, m12045sakata@yahoo.co.jp, ryocky0518@gmail.com, srif_2000@yahoo.com, yshirayo@med.tottori-u.ac.jp, ykazuhiro@med.tottori-u.ac.jp, ninomiya@med.tottori-u.ac.jp, hisatome@med.tottori-u.ac.jp

30-Apr-2013

Dear Author/Co-Author

A revised manuscript entitled "Simultaneous treatment with azelnidipine and olmesartan inhibits apoptosis of HL-1 cardiac myocytes expressing E334K cMyBPC" has been successfully submitted online by Dr. udin bahrudin and is presently being given full consideration for publication in Drug Research.

The manuscript ID is: AMF-2013-01-0213.R1

You can view this manuscript and check the status of papers you have authored/co-authored at any time by checking your "Author Center" after logging in to <http://mc.manuscriptcentral.com/drugres> .

If there are any changes in your street address or e-mail address, please log in to Manuscript Central and edit your user information as appropriate.

Please mention the above manuscript ID in all future correspondence or when calling the Editorial Office for questions.

Thank you for submitting your manuscript to Drug Research.

Yours sincerely,
Jess Harris
Editorial Office
Drug Research
drugresearch@editorialoffice.co.uk



bahrudin udin <bahrudin00@gmail.com>

Re: AMF-2013-01-0213.R1

3 messages

drugresearch@editorialoffice.co.uk <drugresearch@editorialoffice.co.uk>
To: bahrudin00@gmail.com

Fri, May 3, 2013 at 2:41 AM

02-May-2013

AMF-2013-01-0213.R1 - Simultaneous treatment with azelnidipine and olmesartan inhibits apoptosis of HL-1 cardiac myocytes expressing E334K cMyBPC

Dear Dr. Bahrudin,

Before I send your manuscript to production I will need the full postal addresses for both corresponding authors. Please could you email them to me and I will add them to your title page.

Please let me know if you need further clarification.

Sincerely,
Mrs. Jess Harris
Drug Research
drugresearch@editorialoffice.co.uk

bahrudin udin <bahrudin00@gmail.com>
To: drugresearch@editorialoffice.co.uk

Fri, May 3, 2013 at 7:20 AM

Dear Mrs. Jess Harris,

Thank you for your email. The full postal addresses for both corresponding authors are below.

Udin Bahrudin, MD, PhD

Center of Biomedical Research, Faculty of Medicine, Diponegoro University

Jl. Dr. Sutomo 18, Semarang 50231, Indonesia.

Tel. +62-24-8412311, Fax. +62-24-8454714.

Email: bahrudin00@gmail.com

Ichiro Hisatome, MD, PhD.

Division of Regenerative Medicine and Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science

Nishimachi 86, Yonago 683-8503, Japan.

Tel. +81-859-38-6445, Fax. +81-859-38-6440.

E-mail: hisatome@med.tottori-u.ac.jp

Sincerely,

Udin Bahrudin, MD

[Quoted text hidden]

Drug Research <drugresearch@editorialoffice.co.uk>

Sat, May 4, 2013 at 1:45 AM

To: bahrudin udin <bahrudin00@gmail.com>

Dear Dr. Bahrudin

Thank you for sending the full postal addresses for the corresponding authors. I have added them to your manuscript and forwarded all to production.

Best regards

Jess Harris
Editorial Office
Drug Research

[Quoted text hidden]